Cardio Diagnostics Holdings Inc. is a biotechnology company in the healthcare sector that develops and commercializes epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management. Its primary offerings include Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment blood test targeting events like heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease; and Actionable Clinical Intelligence, a platform delivering epigenetic and genetic insights to clinicians for improved chronic care management. The company also provides CardioInnovate360, a research-use-only solution supporting biopharmaceutical discovery and validation for cardiovascular diseases, and HeartRisk, a SaaS platform offering real-time cardiovascular risk intelligence from aggregated clinical data. Cardio Diagnostics Holdings Inc. serves telemedicine providers, concierge practices, longevity clinics, risk-bearing provider organizations, employer organizations, and correctional facilities, leveraging AI-driven multi-omics technology for personalized molecular insights beyond traditional risk factors. Founded in 2017 and headquartered in Chicago, Illinois, it focuses on making cardiovascular care more accessible and precise.